Key clinical point: The novel nonanticoagulant heparinoid drug sevuparin failed to resolve acute vaso-occlusive crisis in patients with SCD but may have a role for preventing VOC.
Major finding: Time to VOC resolution was similar at about 168 hours in the treatment and placebo arms (intention to treat hazard ratio, 0.89).
Study details: A randomized, placebo-controlled, double-blind phase 2 study of 147 patients.
Disclosures: Dr. Biemond reported research funding from Sanquin and honoraria from Novartis and GBT.
Biemond BJ et al. ASH 2019, Abstract 614.